Changes in SARS-CoV-2 full-length spike, RBD, and N binding antibody levels from before vaccination to each subsequent time point, expressed as GMFRs;Changes in SARS-CoV-2 serum neutralizing levels from before vaccination to each subsequent time point, expressed as GMFRs;GMC ratio (ARCT-021/ARCT-165, ARCT-165/ARCT-154, and ARCT-021/ARCT-154);Percentage of participants reporting adverse events leading to discontinuation from study vaccine/study withdrawal;Percentage of participants reporting medically attended adverse events;Percentage of participants reporting serious adverse events;Percentage of participants reporting solicited local or systemic adverse events;Percentage of participants reporting unsolicited adverse events;Percentages of participants achieving greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 full-length spike, RBD, and N binding antibody levels;Percentages of participants achieving greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 serum neutralizing antibody levels;SARS-CoV-2 full-length spike, RBD, and N binding antibody levels, expressed as GMCs;SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs

Changes in SARS-CoV-2 full-length spike, RBD, and N binding antibody levels from before vaccination to each subsequent time point, expressed as GMFRs;Changes in SARS-CoV-2 serum neutralizing levels from before vaccination to each subsequent time point, expressed as GMFRs;GMC ratio (ARCT-021/ARCT-165, ARCT-165/ARCT-154, and ARCT-021/ARCT-154);Percentage of participants reporting adverse events leading to discontinuation from study vaccine/study withdrawal;Percentage of participants reporting medically attended adverse events;Percentage of participants reporting serious adverse events;Percentage of participants reporting solicited local or systemic adverse events;Percentage of participants reporting unsolicited adverse events;Percentages of participants achieving greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 full-length spike, RBD, and N binding antibody levels;Percentages of participants achieving greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 serum neutralizing antibody levels;SARS-CoV-2 full-length spike, RBD, and N binding antibody levels, expressed as GMCs;SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs

Changes in SARS-CoV-2 full-length spike, RBD, and N binding antibody levels from before vaccination to each subsequent time point, expressed as GMFRs;Changes in SARS-CoV-2 serum neutralizing levels from before vaccination to each subsequent time point, expressed as GMFRs;GMT ratio (ARCT-021/ARCT-165, ARCT-165/ARCT-154, and ARCT-021/ARCT-154);Percentage of participants reporting adverse events leading to discontinuation from study vaccine/study withdrawal;Percentage of participants reporting medically attended adverse events;Percentage of participants reporting serious adverse events;Percentage of participants reporting solicited local or systemic adverse events;Percentage of participants reporting unsolicited adverse events;Percentages of participants achieving greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 full-length spike, RBD, and N binding antibody levels;Percentages of participants achieving greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 serum neutralizing antibody levels;SARS-CoV-2 full-length spike, RBD, and N binding antibody levels, expressed as GMCs;SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs

Changes in SARS-CoV-2 full-length spike, RBD, and N binding antibody levels from before vaccination to each subsequent time point, expressed as GMFRs;Changes in SARS-CoV-2 serum neutralizing levels from before vaccination to each subsequent time point, expressed as GMFRs;GMT ratio (ARCT-021/ARCT-165, ARCT-165/ARCT-154, and ARCT-021/ARCT-154);Percentage of participants reporting adverse events leading to discontinuation from study vaccine/study withdrawal;Percentage of participants reporting medically attended adverse events;Percentage of participants reporting serious adverse events;Percentage of participants reporting solicited local or systemic adverse events;Percentage of participants reporting unsolicited adverse events;Percentages of participants achieving greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 full-length spike, RBD, and N binding antibody levels;Percentages of participants achieving greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 serum neutralizing antibody levels;SARS-CoV-2 full-length spike, RBD, and N binding antibody levels, expressed as GMCs;SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs